Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Bioiberica, SAU
WARNING LETTER
•Bioiberica, SAU•February 4, 2022

Bioiberica, SAU – FDA Warning Letter, Feb 4, 2022

Record Details

The FDA inspected Bioiberica, SAU, an API manufacturing facility in Palafolls, Barcelona, from January 31 to February 4, 2022, and found significant deviations from current Good Manufacturing Practice (CGMP). Consequently, the firm's API is deemed adulterated under section 501(a)(2)(B) of the FD&C Act. The inspection revealed three primary violations. First, the firm failed to establish written procedures to monitor and control processing steps causing variability, specifically for approximately 23 reworked batches of (b)(4) USP, API due to microbiological OOS or high (b)(4) content, using an unvalidated industrial (b)(4) without proper monitoring. Second, reworked batches were not subjected to appropriate evaluation and stability testing to confirm equivalent quality to material produced by the original process, with no stability data for marketed reworked batches. Third, the firm lacked an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. The FDA deemed the firm's response inadequate, noting a mischaracterization of rework as reprocessing and a lack of interim measures. The FDA strongly recommended engaging a CGMP consultant. The firm must promptly correct all deviations, provide a written response within 15 working days detailing corrective actions, and address recurrence prevention. Failure to comply may result in withheld approvals, re-inspection, or refusal of admission of products into the U.S.

Company
Bioiberica, SAU
Inspection date
February 4, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Joseph R. Lambert (Compliance Officer, CDER, Office of Manufacturing)
  • Francis Godwin (Director)
View Company Profile

ID · ec452cd4-ba0a-4296-a236-bbe9aa70c4fe

Violation Codes4
21 U.S.C. 351(a)(2)(B)21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bioiberica, SAU
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.